Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Via News Knowledge File

Elf Labs

organization80% conf.·synced Aug 13, 2026

IP-focused entertainment company controlling 500+ trademarks/copyrights for characters including Cinderella, Snow White, Rapunzel, Sleeping Beauty, and Peter Pan; over $15M in royalties

31
sourced metrics
0
relationships
18
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Country Licensing
30count
source
Trademarks Copyrights Owned
500assets
source
Countries Licensed
30count
⚠ sources conflictsource
Country Count
30countries
⚠ sources conflictsource
Country Expansion
30count
source
Country Presence
30countries
source
Distribution Countries
30countries
source
Geographic Reach
30countries
source
Intellectual Property
500trademarks_and_copyrights
source
Intellectual Property Count
500trademarks_copyrights
⚠ sources conflictsource
International Markets
30countries
source
Ip Assets
500trademarks_and_copyrights
source
Licensing Countries
30countries
⚠ sources conflictsource
Licensing Markets
30countries
source
Market Cap
1600USD
⚠ sources conflictsource
Market Expansion
30countries
source
Market Presence
30countries
source
Product Count
100product_lines
source

Stated objectives

Expand investor base through Regulation A+ offering at $0.85/share with $1,000 minimum investment to diversify portfolios into early-stage AI innovation

source
target: 0.85 per share stated

Scale AI marketing platform to help transform data chaos into actionable insights and create high-performing content with measurable ROI

source
stated

Generate measurable ROI for clients through AI-driven content creation and data analytics

source
stated

Provide investors exposure to rapidly growing AI and tech sector at ground-floor stage

source
target: 0.85 per share minimum investment of 1000 USD stated

Elf Labs scaling distribution through patented production systems, global licensing, and streaming and mobile initiatives toward public market listing

source
target: Nasdaq listing under ticker ELFS stated

Scaling distribution through patented production systems, global licensing, and streaming and mobile initiatives

source
stated

Scale distribution through patented production systems, global licensing, and streaming and mobile initiatives toward public market listing on Nasdaq

source
stated

Scaling distribution through patented production systems, global licensing, and streaming and mobile initiatives

source
stated

Scale distribution through patented production systems, global licensing, streaming and mobile initiatives toward public market transition

source
stated

Scale distribution through patented production systems, global licensing, streaming and mobile initiatives toward public market debut

source
stated
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com